CO-NEWMONT-CORPORATION
3.6.2021 13:32:11 CEST | Business Wire | Press release
Today, Newmont Corporation (NYSE: NEM, TSX: NGT) launched its 2020 Annual Sustainability Report , part of the suite of reports on the Company’s environmental, social and governance (ESG) practices in key areas that include health, safety and security, human rights, the environment, social acceptance, governance, and inclusion and diversity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005281/en/
“As we celebrate our 100th year, Newmont’s commitment to sustainable and responsible mining has never been stronger. Our sustainability report provides a comprehensive review of our safety, environmental and social performance,” said Newmont’s President and CEO Tom Palmer. “With this report we offer a transparent review of how we work toward making a positive difference in the lives of our employees, stakeholders, business partners and host communities around the world.”
Highlights of Newmont’s 2020 Sustainability Report:
-
Commitment to health and safety: Achieved the best safety and financial performance in the Company’s history. Investments in our Fatality Risk Management program and a focus on the critical controls that prevent fatalities resulted in Newmont reducing potentially significant events and achieving the lowest injury rate in its history.
-
Response to COVID-19: Activated the Company’s Rapid Response program to preserve the health and safety of the workforce, host and nearby Indigenous communities during the COVID-19 pandemic. Through Newmont’s COVID-19 Global Community Support Fund, the Company has supported communities’ management and recovery from the pandemic in three key areas of need: workforce and community health, food security, and local economic resilience.
-
Addressing climate change: Furthered Newmont’s commitment to environmental stewardship by announcing industry-leading climate change targets of more than a 30 percent reduction in Scope 1 and 2 emissions and a 30 percent reduction in Scope 3 missions by 2030, with an ultimate aspiration of being net zero carbon by 2050. Newmont has committed $500 million over the next five years to support efforts to meeting these goals.
- Continued value sharing: Newmont continued to play an important role in creating economic value in host communities and jurisdictions, contributing $7.7 billion in economic value for its workforce, host communities and jurisdictions through wages and benefits, operating costs, capital spend, royalties, and taxes. This also includes spending $3.9 billion with local and national suppliers and investing $20.5 million in community projects and providing ongoing opportunities for local and Indigenous employment.
Newmont’s sustainability efforts continue to be recognized by several leading independent organizations:
- Recognized as top-ranked gold miner for the sixth consecutive year in the Dow Jones Sustainability Index (DJSI) while continuing to be recognized as the top mining company on FORTUNE’s list of the World’s Most Admired Companies;
- Earned a score of “A-“ from CDP for the CDP Climate assessment, reflecting the coordinated action on climate issues;
- Listed as 6th overall and the top mining company in 3BL’s 100 Best Corporate Citizens;
- Achieved a perfect score of 100 on the Human Rights Campaign Foundation’s Corporate Equity Index for the Company’s work in creating an inclusive workplace for LGBTQ+ employees, and was included in Bloomberg’s Gender-Equality Index (GEI) for Newmont’s efforts to advance women in the workplace; and
- Ranked as the top gold miner in Newsweek’s list of America’s Most Responsible Companies for 2020 and as the second most transparent company in the S&P 500.
Newmont’s 2020 Sustainability Report is written in accordance with the GRI Standards Core option, the GRI Mining and Metals Sector Supplement, the Sustainability Accounting Standards Board (SASB) Metals and Mining protocol, and is externally assured. Additionally, this report aligns with two new disclosure frameworks, ICMM’s Mining Principles’ Performance Expectations and the World Gold Council’s Responsible Gold Mining Principles.
The report continues to demonstrate Newmont’s commitment to transparency and accountability on its most material sustainability topics. To support the investment community in their understanding of the report, and to provide decision-useful information for stakeholders, Newmont will be hosting a webcast on July 8 to discuss the contents of its suite of sustainability reports. The full 2020 Sustainability Report, along with the ESG data tables and a comprehensive GRI/SASB content index, is available for download on Newmont’s website .
About Newmont
Newmont is the world’s leading gold company and a producer of copper, silver, zinc and lead. The Company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical expertise. Newmont was founded in 1921 and has been publicly traded since 1925.
At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, go to www.newmont.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
